Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
142 hedge funds and large institutions have $727M invested in Aerie Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 59 increasing their positions, 45 reducing their positions, and 31 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 45
10% less funds holding
Funds holding: 158 → 142 (-16)
12% less capital invested
Capital invested by funds: $830M → $727M (-$104M)
17% less call options, than puts
Call options by funds: $281K | Put options by funds: $337K
52% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$9.41M |
| 2 |
LCS
Levin Capital Strategies
New York
|
+$7.48M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$6.48M |
| 4 |
DM
Deerfield Management
New York
|
+$5.69M |
| 5 |
MGIM
M&G Investment Management
London,
United Kingdom
|
+$4.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$29.8M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$8.59M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.48M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4M |
| 5 |
BlackRock
New York
|
-$3.97M |
AERI Hedge Fund Activity: Q2 2021 in Review
142 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2021, worth a combined $727M — down 12% from $830M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of AERI and 15 opened new positions — a net loss of 16 holders — while 45 trimmed existing stakes and 59 added.
The largest buyer was William Blair Investment Management, adding an estimated $9.41M. The largest seller was Woodline Partners, cutting an estimated $29.8M.
- 142 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2021, down from 158 in Q1 2021.
- Funds reported $727M of Aerie Pharmaceuticals stock for Q2 2021, down 12% quarter-over-quarter.
- 15 funds opened new Aerie Pharmaceuticals positions in Q2 2021 and 31 closed out, a net change of -16 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2021 was William Blair Investment Management, an estimated $9.41M added.
- The largest Aerie Pharmaceuticals seller in Q2 2021 was Woodline Partners, an estimated $29.8M sold.
Based on aggregated 13F filings for Q2 2021.